The concomitant use of lapatinib and paracetamol - the risk of interaction

Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an analgesic commonly applied to patients with mild or moderate pain and fever. Cancer patients are polymedicated, which involves high risk of drug interactions during therapy. The aim of the study was t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Karbownik, Agnieszka, Szałek, Edyta, Sobańska, Katarzyna, Grabowski, Tomasz, Klupczynska, Agnieszka, Plewa, Szymon, Wolc, Anna, Magiera, Magdalena, Porażka, Joanna, Kokot, Zenon J., Grześkowiak, Edmund
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2018
Matèries:
Preclinical Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153549/
https://ncbi.nlm.nih.gov/pubmed/29464465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0573-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars